Mobile

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002038-39

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To investigate the effects of daily dosing for 24 weeks with RSG XR versus placebo on cognitive function in subjects with mild to moderate Alzheimer’s disease as a function of APOE ε4 status. •To investigate the effects of daily dosing for 24 weeks with RSG XR versus placebo on overall clinical response in subjects with mild to moderate Alzheimer’s disease as a function of APOE ε4. •To estimate the effects of donepezil on cognitive function and overall clinical response in the total population

Critère d'inclusion

  • mild to moderate Alzheimer's Disease

Liens